Iryna Pinchuk

Dr. Iryna Pinchuk serves as a Professor in the Department of Medicine (Division of Gastroenterology and Hepatology) and the Department of Cell and Biological Systems at Penn State University, with significant contributions to the Penn State Cancer Institute's Mechanisms of Carcinogenesis program. Her dual appointments reflect an integrative approach bridging gastrointestinal immunology, cancer research, and stromal cell biology across institutional boundaries.

Her pioneering research centers on mucosal immune dysregulation in inflammatory bowel disease (IBD) and gastrointestinal cancers, with landmark discoveries regarding CD90+ stromal cells (CMFs). She demonstrated CMFs' immunosuppressive role in maintaining mucosal tolerance under normal conditions and their pathological dysfunction in IBD and cancer. Current investigations focus on innate-adaptive immune crosstalk and microbiota-mediated modulation of these interactions, leveraging 15+ years of expertise in human/rodent mucosal immunology, cell biology, and microbiology.

Recent publications (2024-2025) reveal dominant trends in targeting novel molecular pathways for IBD therapeutics, including MK2 inhibition, BRD4 epigenetic regulation, and NF-κB signaling modulation. These studies consistently employ translational approaches using animal models to dissect inflammation mechanisms, fibrosis development, and epithelial barrier integrity, with strong emphasis on clinical applicability for Crohn's disease and ulcerative colitis treatment.

As Principal Investigator, Dr. Pinchuk leads active grants including U.S. Army and Congressionally Directed Medical Research Programs funding (2022-2026) for 'Targeting MK2 for Crohn's Disease,' alongside a completed NIDDK project (2014-2019) on CD90+ stromal cell regulation of Th1/Th17 responses. Her 77 publications and held patent demonstrate sustained research productivity, though specific student mentorship details remain unlisted in available materials.

Her laboratory operates within the Penn State Cancer Institute ecosystem, directing a multidisciplinary team that integrates immunology, gastroenterology, and microbiology expertise. The research program utilizes advanced human tissue analysis and rodent models to investigate gastrointestinal mucosal immunity, with active collaborations spanning microbiome analysis, antimicrobial defense mechanisms, and stromal-immune interactions in disease pathogenesis.